A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date4/8/221/30/26

Funding

  • Astellas Pharma Global Development Incorporated: $201,925.00